Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥20.79 |
52 Week High | CN¥33.17 |
52 Week Low | CN¥14.81 |
Beta | 0.48 |
1 Month Change | -2.39% |
3 Month Change | 26.31% |
1 Year Change | -32.70% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -54.68% |
Recent News & Updates
Recent updates
Shareholder Returns
2932 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | 4.4% | 5.3% | 3.1% |
1Y | -32.7% | -13.9% | -13.1% |
Return vs Industry: 002932 underperformed the CN Medical Equipment industry which returned -13.9% over the past year.
Return vs Market: 002932 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
2932 volatility | |
---|---|
2932 Average Weekly Movement | 7.8% |
Medical Equipment Industry Average Movement | 7.9% |
Market Average Movement | 8.6% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002932's share price has been volatile over the past 3 months.
Volatility Over Time: 002932's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 1,547 | Chen Li Li | www.mdeasydiagnosis.com |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Fundamentals Summary
2932 fundamental statistics | |
---|---|
Market cap | CN¥4.83b |
Earnings (TTM) | CN¥515.33m |
Revenue (TTM) | CN¥3.69b |
9.4x
P/E Ratio1.3x
P/S RatioIs 2932 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2932 income statement (TTM) | |
---|---|
Revenue | CN¥3.69b |
Cost of Revenue | CN¥2.02b |
Gross Profit | CN¥1.67b |
Other Expenses | CN¥1.15b |
Earnings | CN¥515.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.22 |
Gross Margin | 45.26% |
Net Profit Margin | 13.98% |
Debt/Equity Ratio | 2.2% |
How did 2932 perform over the long term?
See historical performance and comparison